10x Genomics (NASDAQ:TXG) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of 10x Genomics (NASDAQ:TXG) from a hold rating to a buy rating in a research note released on Friday morning.

TXG has been the topic of several other reports. Canaccord Genuity Group set a $16.00 target price on shares of 10x Genomics in a research note on Monday, August 11th. Morgan Stanley cut their price target on shares of 10x Genomics from $18.00 to $17.00 and set an “overweight” rating on the stock in a report on Tuesday, August 12th. Barclays restated an “overweight” rating and issued a $15.00 price objective (up previously from $13.00) on shares of 10x Genomics in a research report on Friday, August 8th. Piper Sandler began coverage on shares of 10x Genomics in a report on Thursday, September 11th. They set a “neutral” rating and a $15.00 target price for the company. Finally, Zacks Research cut 10x Genomics from a “strong-buy” rating to a “hold” rating in a research note on Friday, September 5th. Six research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat, 10x Genomics has a consensus rating of “Hold” and a consensus target price of $13.65.

10x Genomics Trading Up 3.6%

TXG opened at $12.75 on Friday. 10x Genomics has a 12 month low of $6.78 and a 12 month high of $20.92. The business’s 50-day moving average price is $13.17 and its 200-day moving average price is $11.01. The company has a market cap of $1.59 billion, a P/E ratio of -18.21 and a beta of 2.05.

10x Genomics (NASDAQ:TXG) last issued its earnings results on Thursday, August 7th. The company reported $0.28 earnings per share for the quarter, beating the consensus estimate of ($0.35) by $0.63. The company had revenue of $172.91 million during the quarter, compared to analysts’ expectations of $139.36 million. 10x Genomics had a negative return on equity of 12.88% and a negative net margin of 13.13%.10x Genomics’s quarterly revenue was up 12.9% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.32) EPS. 10x Genomics has set its Q3 2025 guidance at EPS. Equities research analysts forecast that 10x Genomics will post -1.43 earnings per share for the current fiscal year.

Insider Buying and Selling at 10x Genomics

In related news, CFO Adam Taich sold 22,315 shares of 10x Genomics stock in a transaction that occurred on Friday, August 22nd. The stock was sold at an average price of $13.79, for a total transaction of $307,723.85. Following the sale, the chief financial officer directly owned 309,273 shares in the company, valued at $4,264,874.67. The trade was a 6.73% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Serge Saxonov sold 9,348 shares of the company’s stock in a transaction on Friday, August 22nd. The stock was sold at an average price of $13.79, for a total value of $128,908.92. Following the completion of the sale, the chief executive officer directly owned 945,892 shares in the company, valued at approximately $13,043,850.68. The trade was a 0.98% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 39,149 shares of company stock valued at $539,865. 10.03% of the stock is currently owned by corporate insiders.

Institutional Trading of 10x Genomics

Hedge funds have recently modified their holdings of the business. ARK Investment Management LLC grew its position in shares of 10x Genomics by 8.1% in the 2nd quarter. ARK Investment Management LLC now owns 13,892,103 shares of the company’s stock worth $160,871,000 after buying an additional 1,046,390 shares during the period. Vanguard Group Inc. boosted its stake in 10x Genomics by 1.7% during the first quarter. Vanguard Group Inc. now owns 11,118,086 shares of the company’s stock worth $97,061,000 after acquiring an additional 184,537 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its holdings in 10x Genomics by 235.6% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 7,103,768 shares of the company’s stock worth $62,016,000 after purchasing an additional 4,987,195 shares during the period. Sumitomo Mitsui Trust Group Inc. grew its holdings in 10x Genomics by 12.2% in the second quarter. Sumitomo Mitsui Trust Group Inc. now owns 6,017,963 shares of the company’s stock worth $69,688,000 after purchasing an additional 654,597 shares during the period. Finally, Nikko Asset Management Americas Inc. increased its stake in shares of 10x Genomics by 12.1% during the second quarter. Nikko Asset Management Americas Inc. now owns 6,009,653 shares of the company’s stock valued at $69,532,000 after purchasing an additional 646,997 shares in the last quarter. Institutional investors own 84.68% of the company’s stock.

10x Genomics Company Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.